Beta test rollout. This site is in community QA — please send feature requests, bug reports and data corrections on the Feedback page or on GitHub.

Home
    Disclaimer
    Flubrotizolam molecular structure

    Flubrotizolam Stats & Data

    Fanax
    NPS DataHub
    MW377.24
    FormulaC15H10BrFN4S
    CAS57801-95-3
    IUPAC2-bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
    SMILESFc1ccccc1C1=NCc2nnc(C)n2c2sc(Br)cc12
    InChIKeyVOZDBDBHBXLWCG-UHFFFAOYSA-N
    Benzodiazepines
    Chemical Class Thienotriazolodiazepine
    Psychoactive Class Depressant

    Effect Profile

    Curated + 3 Reports
    Benzodiazepine 7.6

    Strong anxiolysis and euphoria with moderate cognitive impairment, mild sedation

    Anxiolysis×3
    10
    Sedation / Relaxation×2
    5
    Motor / Cognitive Impairment×1
    7
    Euphoria / Mood Lift×1
    10
    Based on reports from:

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; user reports suggest prolonged effects and next‑day sedation despite short perceived primary phase.
    Addiction Potential
    High; like other benzodiazepines and thienotriazolodiazepines, repeated use can rapidly produce tolerance, physiological dependence, and a difficult withdrawal syndrome.

    No tolerance chart. Our decay curves for these drugs were estimates, and a curve can make tolerance look longer-lasting than it is, which is the dangerous direction.

    How fast tolerance to these drugs fades after a break has not been measured well enough to draw, so don't count on a dose you used to take still being safe: after time off, start with a much smaller amount and don't use alone. Mixing sedatives with each other, with alcohol or with opioids sharply raises the risk of a fatal overdose. If you've been using regularly, don't stop suddenly: withdrawal from benzodiazepines, alcohol or GHB/GBL can cause seizures or delirium, so get medical help to cut down gradually.

    Sources: FRANK: benzodiazepines · Alcohol and Drug Foundation: GHB · FDA 2020: benzodiazepine boxed warning · FDA 2019: gabapentinoids and breathing · NHS: alcohol use disorder

    Cross-Tolerances

    Benzodiazepines
    Z-drugs

    Experience Report Analysis

    Erowid
    3 Reports
    2022–2023 Date Range
    3 With Age Data
    1 Effects Detected

    Demographics

    Gender Distribution

    Too few reports for a chart: gender is known from 3 reports, and a split is drawn only from 20 reports or more. Counts are shown instead. Why 20?

    • Male 2 of 3
    • Not Specified 1 of 3

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 3 experience reports (3 single-substance Erowid)

    3 Reports
    1 Effects Detected
    1 Positive
    0 Adverse
    0 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

    Too few reports for bars: these effects come from 3 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

    Positive Effects 1

    Sedation 3 of 3 70%

    Adverse Effects 0

    Harm Reduction

    drugs.wiki

    • Identity and synonyms: Flubrotizolam is a thienotriazolodiazepine; synonyms reported in chemical databases include Flurotizolam and research code LS‑152,574. This helps avoid confusion with similarly named benzodiazepines when checking results or labels.

    • Potency: Active doses are typically in the sub‑milligram range; inaccurate measurement greatly increases risks of amnesia, injury, and respiratory depression. Volumetric dosing is recommended for solutions or powders to achieve microgram‑level accuracy.

    • Onset and duration: Oral onset can be delayed up to 45–60 minutes with peaks at 1–3 hours; this lag increases the risk of impatient redosing and subsequent blackout. Plan doses with the delayed onset in mind.

    • Next‑day sedation: Numerous user reports describe marked next‑day impairment and sedation; avoid driving or hazardous tasks for at least 24 hours after significant dosing.

    • Tolerance and dependence: Tolerance can escalate quickly with daily or binge use; spacing doses and avoiding consecutive‑day use lowers risk of rapid tolerance and severe withdrawal.

    • Interactions: Combining with other CNS depressants (alcohol, opioids, GHB/GBL, barbiturates, Z‑drugs, gabapentinoids) can cause unpredictable synergy leading to loss of consciousness and life‑threatening respiratory depression. Avoid polydrug depressant use.

    • Mislabeling/adulteration: RC “Xanax” or “FANAX” style bars and benzo solutions may contain unexpected actives or stimulant admixtures; use reputable drug‑checking services where available and do not assume branding reflects contents.

    • Overdose management: Primary treatment is supportive airway and breathing management; flumazenil can precipitate seizures or acute withdrawal in benzodiazepine‑tolerant individuals or mixed overdoses and should only be used by clinicians under appropriate indications.

    • Route of administration: Non‑oral routes (e.g., injection, inhalation) increase harm without proven benefit; sublingual/oral routes are preferred if one chooses to use.

    • Memory effects: Anterograde amnesia and “false sobriety” are common; pre‑plan environment, remove hazards, and avoid important tasks or conflict‑prone situations when under the influence.

    • Product variability: Different vendors and batches vary in concentration and excipients; start with very small test doses from a new batch, even if experienced.

    • Legal status and availability can change; possession may carry legal risk. Always verify current local regulations before obtaining or transporting substances.

    ← Back to Flubrotizolam